Nasopharyngeal Cancer Pipeline Insight

DelveInsight’s, “Nasopharyngeal Cancer – Pipeline Insight, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Nasopharyngeal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

  • • Global coverage

Nasopharyngeal Cancer Understanding

Nasopharyngeal Cancer: Overview

Nasopharyngeal cancer is a rare type of head and neck cancer. It starts in the nasopharynx, the upper part of the throat behind the nose and near the base of skull. In early cases Nasopharyngeal cancer may not cause any symptoms. The possible symptoms may include: lump in neck, blood in saliva, frequent ear infections, sore throat, nasal congestion, hearing loss. Tests and procedures used to diagnose nasopharyngeal carcinoma include: physical exam, nasal endoscopy and biopsy. Treatment for nasopharyngeal carcinoma usually begins with radiation therapy or a combination of radiation and chemotherapy.


"Nasopharyngeal Cancer - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nasopharyngeal Cancer pipeline landscape is provided which includes the disease overview and Nasopharyngeal Cancer treatment guidelines. The assessment part of the report embraces, in depth Nasopharyngeal Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nasopharyngeal Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence R&D. Nasopharyngeal Cancer The therapies under development are focused on novel approaches to treat/improve Nasopharyngeal Cancer.

Nasopharyngeal Cancer Emerging Drugs Chapters

This segment of the Nasopharyngeal Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Nasopharyngeal Cancer Emerging Drugs


Sintililimab: Innovent Biologics (Suzhou) Co. Ltd.

Sintilimab, a highly selective fully human IgG4 monoclonal antibody, blocks the binding site of programmed cell death protein 1 (PD-1), thereby, inhibiting the interaction between PD-1 and its ligands (PD-L1/2) to restore the endogenous anti-tumor T cell responses. The clinical trials for sintilimab are being evaluated for the treatment of Nasopharyngeal Neoplasms in phase III stage of development.


Tislelizumab: BioGene

Tislelizumab (BGB-A317) is a humanized IgG4 anti–PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. Tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers. It is being studied in phase III stage of development for the treatment of Recurrent or Metastatic Nasopharyngeal Cancer.


Tabelecleucel: Atara Biotherapeutics Inc.

Tabelecleucel, tab‐cel® is an off-the-shelf, allogeneic T-cell immunotherapy in phase I/II studies for the treatment of nasopharyngeal carcinoma.


PDR001: Novartis Pharmaceuticals

PDR001 (anti-PD-1) is an investigational immunotherapy being developed by Novartis to treat both solid tumors and lymphomas. PDR001 is a type of immunotherapy, it acts by activating the body’s own immune system to recognize and fight cancer cells. The drug is being studied in phase II stage of development for the treatment of Nasopharyngeal cancer.

Further product details are provided in the report……..

Nasopharyngeal Cancer: Therapeutic Assessment

This segment of the report provides insights about the different NASOPHARYNGEAL CANCER drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Nasopharyngeal Cancer

There are approx. 10+ key companies which are developing the therapies for NASOPHARYNGEAL CANCER. The companies which have their Nasopharyngeal Cancer drug candidates in the most advanced stage, i.e. phase III include, Innovent Biologics.

Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Nasopharyngeal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Subcutaneous
  • Intravenous
  • Intramuscular
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Bispecific Antibody
  • Peptides
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Nasopharyngeal Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Nasopharyngeal Cancer therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nasopharyngeal Cancer drugs.

Nasopharyngeal Cancer Report Insights

  • Nasopharyngeal Cancer Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Nasopharyngeal Cancer Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Nasopharyngeal Cancer drugs?
  • How many Nasopharyngeal Cancer drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nasopharyngeal Cancer?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Nasopharyngeal Cancer therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Nasopharyngeal Cancer and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Nasopharyngeal Cancer: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Nasopharyngeal Cancer – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

  • NASOPHARYNGEAL CANCER companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Nasopharyngeal Cancer Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

  • Comparative Analysis

Sintililimab: Innovent Biologics (Suzhou) Co. Ltd.

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

PDR001: Novartis Pharmaceuticals

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

SHR-1701: Jiangsu Hengrui Medicine Co.

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Preclinical Stage Products

  • Comparative Analysis

Drug Name: Company name

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Nasopharyngeal Cancer Key Companies

Nasopharyngeal Cancer Key Products

Nasopharyngeal Cancer - Unmet Needs

Nasopharyngeal Cancer - Market Drivers and Barriers

Nasopharyngeal Cancer - Future Perspectives and Conclusion

Nasopharyngeal Cancer Analyst Views

Nasopharyngeal Cancer Key Companies

Appendix

List of Table

Table 1: Total Products for Nasopharyngeal Cancer

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Nasopharyngeal Cancer

Figure 2: Late Stage Products                               

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products    

•  Novartis Pharmaceuticals

•  innovent Biologics

•  BeiGene

•  Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

•  Merck Sharp & Dohme Corp.

•  Tessa Therapeutics

•  Akeso Pharmaceuticals, Inc.

•  Jiangsu HengRui Medicine Co., Ltd.

•   Atara biotherapeutics

•  Incyte Corporation

•  Bristol-Myers Squibb

•  Hoffman La Roche

•   Betta Pharmaceuticals Co., Ltd.

•  Incyte Corporation

•  Bristol-Myers Squibb

•  Hoffman La Roche

•  Klus Pharma

  • Tags:
  • Nasopharyngeal Cancer Pipeline
  • Nasopharyngeal Cancer clinical tri...
  • Nasopharyngeal Cancer companies
  • Nasopharyngeal Cancer drugs
  • Nasopharyngeal Cancer therapies
  • Nasopharyngeal Cancer treatment al...
  • Nasopharyngeal Cancer pipeline dru...
  • Nasopharyngeal Cancer pipeline com...

Forward to Friend

Need A Quote